secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2026-08-13T20:20:17+00:00
Accession:  0001171843-26-005499
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Q3 net loss of $5.4M; advances EB06 vitiligo Phase 2
--------------------------------------------------------------------------

- Q3 net loss $5.4M ($0.60/share) vs $1.7M ($0.25) year ago; nine-month loss $11.9M ($1.40) vs $5.0M ($0.95).
- R&D expenses rose $3.1M to $4.0M in Q3 on EB06 manufacturing and prep; total opex $5.5M vs $1.9M.
- Cash and equivalents $10.3M, working capital $6.9M at June 30, 2026.
- EB06 Phase 2 vitiligo study prep complete; first sites activating, recruitment to start in coming weeks in Canada.
- Paridiprubart exploratory data in ARDS with AKI showed significant mortality reduction and improved MAKE30 endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326005499/0001171843-26-005499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326005499/f8k_081226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer